Nuvectis Pharma is a biopharmaceutical company focused on the development of medicines for the treatment of medical needs in oncology. Co. uses target selection, drug profiling, and clinical and regulatory execution to build a pipeline of anticancer targeted-therapy drugs. Co. is developing two preclinical drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule inhibitor of the Heat Shock Factor 1 pathway. NXP800 targets ovarian clear cell carcinoma and endometrioid ovarian cancer. NXP900 is an oral small molecule designed to inhibit the SRC and YES1 kinases. NXP900 is in preclinical development with IND-enabling studies. We show 6 historical shares outstanding datapoints in our NVCT shares outstanding history coverage, used to compute NVCT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NVCT market cap history over the course of time is important for investors
interested in comparing NVCT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NVCT versus a peer is one thing; comparing
NVCT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NVCT can fluctuate over the course of history.
With this page we aim to empower investors researching NVCT by allowing them to research the NVCT market cap history. |
Free NVCT Email Alerts:
Video: The Importance of Market Cap
